Google
EQ — EQUILLIUM INC (Healthcare >> Biotechnology)
EQ FAQ
What is EQ's ROE?
EQUILLIUM INC reports a Return on Equity (ROE) of -32.03%.
What is EQ's dividend yield?
EQUILLIUM INC offers a dividend yield of 0.00%.
What is EQ's Deepscope Quality Score?
Deepscope rates EQ's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy EQ?
Deepscope's AI Timing Score for EQ is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does EQ belong to?
EQUILLIUM INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.17
Price
-0.23
(-7.26%)
Day Change
|
|
|---|
EQ, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.17 |
| PBV / Sector |
2.97 / 4.58
|
| Earning Per Share | -0.34 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
2.99 M
GREAT
|
| Average 1W Daily Value |
8.31 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:35 |
| Symbol | EQ |
| Name | EQUILLIUM INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 63.23 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 176.40 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037
Phone: 858 240 1200
Website: https://www.equilliumbio.com
Sector: Healthcare >> Biotechnology
Description: Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
